logo

  • The Company
    The Company
      • Promore Pharma in Brief
      • Vision and Strategy
      • Market
      • Team
      • Board of Directors
  • Projects
    Projects
      • Project Overview
      • Ensereptide – Prevention of Post-Surgical Adhesions and Scars
      • Ropocamptide – Healing of Chronic Wounds
      • Publications
  • Investors
    Investors
      • Promore Pharma on Nasdaq First North Growth Market
        • Certified Adviser
      • The Share
        • Shareholders
        • Warrant Programs
        • Share capital development
        • Analysts
      • Financial Reports
      • Press Releases
      • Prospectuses
      • Presentations and Events
      • Calendar
      • Subscribe
  • Corporate Governance
    Corporate Governance
      • Corporate Governance
      • General Meeting
        • General Meetings
      • Nomination Committee
        • Nomination Committees
      • The Board of Directors
        • Board of Directors
      • The Management
        • Management
      • Remunerations and Remuneration Committee
      • Auditor and Audit Committee
      • Articles of Association
      • Certificate of Registration
  • Media
    Media
      • Press Releases
      • Imagebank
      • Promore Pharma in Media
      • Subscribe
  • Contact
    Contact
      • Office
      • Investors
      • Media
Svenska
The Company
  • Promore Pharma in Brief
  • Vision and Strategy
  • Market
  • Team
  • Board of Directors
Projects
  • Project Overview
  • Ensereptide – Prevention of Scarring
  • Ropocamptide – Healing of Chronic Wounds
  • Publications
Investors
  • Promore Pharma on Nasdaq First North Growth Market
    • Certified Adviser
  • The Share
    • Shareholders
    • Warrant Programs
    • Share capital development
    • Analysts
  • Financial Reports
  • Press Releases
  • Prospectuses
  • Presentations and Events
  • Calendar
  • Subscribe
Corporate Governance
  • Corporate Governance
  • General Meeting
    • General Meetings
  • Nomination Committee
    • Nomination Committees
  • The Board of Directors
    • Board of Directors
  • The Management
    • Management
  • Remunerations and Remuneration Committee
  • Auditor and Audit Committee
  • Articles of Association
  • Certificate of Registration
Media
  • Press Releases
  • Imagebank
  • Promore Pharma in Media
  • Subscribe
Contact
  • Office
  • Investors
  • Media

Media

  • Press Releases
  • Imagebank
  • Promore Pharma in Media
  • Subscribe

Contact

Erik Magnusson

Chief Financial Officer (CFO) +46 70 856 52 45

Press Releases

All press releases
  • Regulatory press releases
  • Non-regulatory press releases
2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2013
  • All years
June 13, 2022

The last clinic visit conducted in Promore Pharma’s phase II study of ensereptide

May 17, 2022

Report from the Annual General Meeting of Promore Pharma AB held on 17 May 2022

May 17, 2022

Promore Pharma — interim report January-March 2022

May 13, 2022

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2022

April 26, 2022

Promore Pharma’s Annual Report 2021 and AGM related Documents Published

April 12, 2022

NOTICE OF ANNUAL GENERAL MEETING PROMORE PHARMA AB (PUBL)

March 17, 2022

Promore Pharma has reached recruitment goal in clinical trial of ensereptide

February 16, 2022

Interim report January – December 2021

February 16, 2022

First patient recruited to Promore Pharma’s clinical trial regarding scarring according to plan

February 9, 2022

Invitation to Conference Call regarding Promore Pharma’s Year-end Report 2021

January 31, 2022

Promore Pharma deregisters warrants

The Company
  • Promore Pharma in Brief
  • Vision and Strategy
  • Market
  • Team
  • Board of Directors
Projects
  • Project Overview
  • Ensereptide – Prevention of Scarring
  • Ropocamptide – Healing of Chronic Wounds
  • Publications
Investors
  • Promore Pharma on Nasdaq First North Growth Market
  • The Share
  • Financial Reports
  • Press Releases
  • Prospectuses
  • Presentations and Events
  • Calendar
  • Subscribe
Corporate Governance
  • Corporate Governance
  • General Meeting
  • Nomination Committee
  • The Board of Directors
  • The Management
  • Remunerations and Remuneration Committee
  • Auditor and Audit Committee
  • Articles of Association
  • Certificate of Registration
Media
  • Press Releases
  • Imagebank
  • Promore Pharma in Media
  • Subscribe
Contact
  • Office
  • Investors
  • Media

Promore Pharma AB. Address: Fogdevreten 2, SE-171 65 Solna, Sweden. Phone: +46 8 124 548 59. E-mail: info@promorepharma.com. Registration number: 556639-6809.

  • Personal data
  • About cookies